# Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis

> **NCT07670130** · — · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 50 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07670130
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670130, "Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*